Jazz Pharmaceuticals JAZZ Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's long-term debt?
- Jazz Pharmaceuticals (JAZZ) reported long-term debt of $4.32B in Q1 2026.
- How has Jazz Pharmaceuticals's long-term debt changed year-over-year?
- Jazz Pharmaceuticals's long-term debt decreased by 19.0% year-over-year, from $5.34B to $4.32B.
- What is the long-term trend for Jazz Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's long-term debt has grown at a 18.5% compound annual growth rate (CAGR), from $1.85B to $4.33B.
- What does long-term debt mean?
- Total debt obligations due after more than one year.
- How do you interpret long-term debt?
- High levels indicate significant financial leverage, which can amplify returns but also increase financial risk and interest expense.
- How does long-term debt compare across companies?
- Compared across peers using Debt-to-EBITDA ratios to assess relative financial risk.